Clinical Trial

Clinical Study on the Treatment of MIBC Patients With SHR-A2102 Injection Combined With Adebrelimab (SHR-1316)

Recruiting Phase 2/3
View on ClinicalTrials.gov →
Summary
In phase II, the main objective is to evaluate the efficacy of SHR-A2102 combined with Adebrelimab in the treatment of muscular invasive bladder cancer (MIBC); The main objective of phase III is to evaluate the efficacy of SHR-A2102 for injection combined with Adebrelimab compared with gemcitabine combined with cisplatin in the treatment of muscular invasive bladder cancer (MIBC).
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2025-03-11; most recent amendment 2026-07-09.
Status change: Not Yet Recruiting → Recruiting 2025-06-17
Trial Details
NCT Number NCT06879145
Lead Sponsor Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Conditions Muscular Invasive Bladder Cancer (MIBC)
Enrollment 840 participants
Start Date 2025-04-25
Primary Completion 2031-12 (estimated)
Study Completion 2031-12 (estimated)
Updated on ClinicalTrials.gov 2026-07-13